Antiviral Therapy and Post‐Resection Outcomes in Patients With Hepatitis B Virus‐Related Hepatocellular Carcinoma
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70850 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2026. Written by Jaehong Jeong and 10 co-authors. Institution: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. Major MEDLINE topics: Carcinoma, Hepatocellular, Antiviral Agents, Liver Neoplasms, Hepatitis B, Chronic. Cited 6 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background & Aims The comparative outcomes of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) in patients with hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) after curative resection remain unclear. This study aimed to evaluate the survival benefits of these antiviral regimens in a large real‐world cohort.
Methods
We analysed 902 patients with BCLC stage 0 or A HBV‐related HCC who underwent curative resection between September 2001 and August 2025. Patients received ETV ( n = 474), TDF ( n = 363), or TAF ( n = 65) as first‐line therapy within 3 months post‐resection. Inverse probability of treatment weighting (IPTW) was implemented to balance baseline covariates. The primary and secondary endpoints were overall survival (OS) and recurrence‐free survival (RFS).
Results
The IPTW‐adjusted 5‐year OS rates for ETV, TDF, and TAF were 90.7%, 95.2%, and 97.1%, respectively (global p = 0.079). The 5‐year RFS rates were comparable for ETV, TDF, and TAF (57.4% vs. 61.0% vs. 69.4%; global p = 0.533). In multivariable Cox regression analysis, however, TDF was independently associated with a significantly lower risk of death compared with ETV (aHR 0.48; 95% CI, 0.26–0.89; p = 0.021). TAF showed higher survival rates compared to ETV, although the difference did not reach statistical significance (aHR 0.34; 95% CI, 0.04–2.55; p = 0.292).
Conclusion
The choice of antiviral regimen was not associated with RFS after curative resection for HBV‐related HCC, whereas TDF was independently associated with improved OS compared with ETV. Further large‐scale studies are warranted to validate the long‐term prognostic impact of TAF.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
- Yonsei Liver Center, Severance Hospital, Seoul, Korea.
ORCID profiles: Jaehong Jeong, Jung Pyo Hong, Dong Yun Kim, Jae Seung Lee, Mi Na Kim, Seung Up Kim, Sang Hoon Ahn, Hye Won Lee
Cite
APA
Jeong, J., Hong, J. P., Kim, D. Y., Lee, J. S., Kim, M. N., Kim, S. U., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., & Lee, H. W. (2026). Antiviral Therapy and Post‐Resection Outcomes in Patients With Hepatitis B Virus‐Related Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70850
Vancouver
Jeong J, Hong JP, Kim DY, Lee JS, Kim MN, Kim SU, et al. Antiviral Therapy and Post‐Resection Outcomes in Patients With Hepatitis B Virus‐Related Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70850
BibTeX
@article{Jeong2026,
author = {Jeong, Jaehong and Hong, Jung Pyo and Kim, Dong Yun and Lee, Jae Seung and Kim, Mi Na and Kim, Seung Up and Kim, Beom Kyung and Park, Jun Yong and Kim, Do Young and Ahn, Sang Hoon and Lee, Hye Won},
title = {Antiviral Therapy and Post‐Resection Outcomes in Patients With Hepatitis B Virus‐Related Hepatocellular Carcinoma},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70850}
}
EUVIMED